Star Plus Legend Holdings Sees Sales Rise to ¥354 Million in First Half of 2025, Stock Surges 112% Despite Decline in Net Income

Star Plus Legend Holdings reported a 112% surge in its stock price over the last quarter, despite mixed financial results for the first half of 2025. Sales increased to CNY 354 million, but net income and earnings per share declined. The company's strategic alliances, including new collaborations in consumer-grade robotics and cultural-tourism initiatives, may have contributed to investor optimism.

Legend Biotech Corporation (NASDAQ:LEGN) experienced a significant 112% surge in its stock price over the last quarter, despite mixed financial results for the first half of 2025. Sales increased to CNY 354 million, but net income and earnings per share declined. The company's strategic alliances, including new collaborations in consumer-grade robotics and cultural-tourism initiatives, may have contributed to investor optimism Nomura Holdings Inc. Makes New $276,000 Investment in Legend Biotech Corporation Sponsored ADR $LEGN^[1].

Analysts maintain a positive outlook for Legend Biotech, with ten analysts rating it a Buy and a current average price target of $74.22 Nomura Holdings Inc. Makes New $276,000 Investment in Legend Biotech Corporation Sponsored ADR $LEGN^[1]. Despite the recent volatility, several institutional investors and hedge funds have added to their stakes in the company. GF Fund Management CO. LTD., Rhumbline Advisers, Mitsubishi UFJ Asset Management Co. Ltd., GAMMA Investing LLC, and Shell Asset Management Co. all increased their holdings in Legend Biotech during the first quarter Nomura Holdings Inc. Makes New $276,000 Investment in Legend Biotech Corporation Sponsored ADR $LEGN^[1].

Legend Biotech reported its second-quarter earnings for 2025, showcasing substantial revenue growth. The company achieved revenue of $255.06 million, surpassing analyst forecasts of $234.23 million. Despite this revenue success, Legend Biotech posted a larger-than-expected loss per share of $0.34, which was below the anticipated loss of $0.1153 BeiGene stock falls on Trump EO concerns, RBC sees buying opportunity^[2]. The company announced the appointment of Carlos Santos as its new Chief Financial Officer, effective immediately, who will focus on maintaining a strong financial position and steering the company toward profitability by 2026 BeiGene stock falls on Trump EO concerns, RBC sees buying opportunity^[2].

The appointment of Carlos Santos and the company's ongoing efforts to strengthen its financial and operational standing may indicate a turnaround in the company's fortunes. RBC Capital raised its price target for Legend Biotech to $77, maintaining an Outperform rating BeiGene stock falls on Trump EO concerns, RBC sees buying opportunity^[2].

In conclusion, while Legend Biotech's financial results for the first half of 2025 were mixed, the company's strategic alliances and strong analyst support suggest a promising future. Investors should keep an eye on the company's quarterly earnings and strategic initiatives for further insights.